FindTrial
Sign In

Systemic SGLT2 Inhibition for Diabetic Macular Edema: A Scoping Review

Systemic SGLT2 Inhibition for Diabetic Macular Edema: A Scoping Review - Systemic SGLT2 Inhibition for Diabetic Macular Edema: A Scoping Review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000061304
Enrollment
20
Registered
2026-04-18
Start date
2026-04-18
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaetic Maclar Edema

Interventions

None listed

Sponsors

Kimitsu Chuo Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Articles found on PubMed using the following search terms: Diaetic Maclar Edema, Diaetic Maclar Oedema, Diabetic Retinopathy and SGLT2 inhibitor

Exclusion criteria

Exclusion criteria: Publications that do not mention diabetic macular edema Publications concerning macular edema not caused by diabetic macular edema Comments on the paper

Design outcomes

Primary

MeasureTime frame
The usefulness of SGLT2 inhibitors for diabetic macular edema will be evaluated based on 1) prevention of the onset of diabetic macular edema, 2) prevention of the progression of diabetic retinopathy, and 3) reduction of the need for therapeutic intervention for diabetic macular edema.—

Countries

Japan,Asia(except Japan),North America

Contacts

Public ContactRyoichi Ishibashi

Kimitsu Chuo Hospital Division of Diabetes, Endocrinology and Metabolism

bassyna6ce1484@yahoo.co.jp0438-36-1071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026